JPRN-UMIN000038085招募中未知
An investigation into the efficacy of modulated CBT for patients with acquired brain injury suffering from anger management difficulties. -A multi-center randomized controlled trial. - CBT-ABI project(RCT)
Keio University School of Medicine, Department of Neuropsychiatry0 个研究点目标入组 40 人开始时间: 2019年9月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 60years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •-Those under any treatment (or therapy is required) for substance-related disorders (except nicotine addiction) -Those with too severe psychiatric or neurological disorders to attend the research -Those with severe medical complication such as live dysfunction, renal dysfunction, endocrine disease -Those ineligible to MRI implementation due to implanted metal in the body, tattoos or other reasons -Those receiving any specific intensive psychotherapy including CBT elsewhere during the trial -Those judged as no therapeutic indication of CBT by the researchers -Strong suicidal ideation
研究者
相似试验
招募中
不适用
The comparison of the effectiveness of approach CBT and ACT on sexual function and sexual schemas in postmenopausal womeSexual Function.IRCT20200428047230N1Islamic Azad University45
招募中
2 期
A comparison of two modalities of Trans cranial Magnetic Stimulation on the excitability brain in children and adolescents aged 5-14years with Drug refractory EpilepsyCTRI/2022/09/045152All India Institute of Medical Sciences
进行中（未招募）
不适用
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuriadiabetes mellitus type II and albuminuriaMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2011-005710-11-DEOXXON Pharma AG75
进行中（未招募）
不适用
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuriadiabetes mellitus type II and albuminuriaMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2011-005710-11-CZOXXON Pharma AG75
进行中（未招募）
不适用
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuriadiabetes mellitus type II and albuminuriaMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2011-005710-11-HUOXXON Pharma AG75